What do the numbers say about Wockhardt Ltd. (WOCKPHARMA)? Here's a look at its financials, valuation, and ownership data.
Wockhardt Revenue Trend
Wockhardt Ltd. managed to grow its top line 7.6% in FY2025, with revenue hitting ₹3,012 Cr.
Revenue has contracted at 3.9% per year over 10 years, from ₹4,482 Cr to ₹3,012 Cr. The decline is gradual, but the direction is clear.
In terms of scale, Wockhardt Ltd.'s ₹3,012 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹3,012 Cr | +7.6% |
| FY2024 | ₹2,798 Cr | +5.5% |
| FY2023 | ₹2,651 Cr | -17.9% |
| FY2022 | ₹3,230 Cr | +19.3% |
| FY2021 | ₹2,708 Cr | — |
View Wockhardt Ltd.'s full 10-year revenue trend with CAGR analysis →
Wockhardt Profitability
Per-share earnings moved to ₹-3.02 in FY2025 from ₹-32.05 in FY2024.
Is Wockhardt Undervalued
Wockhardt Ltd. shares are currently trading at ₹2,028.40.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Wockhardt Shareholding Pattern
At 49.1%, the promoter stake has been flat for the past 4 quarters.
Foreign investors held 7.2% of the company as of June 2026, up year-over-year from 7.1%.
Domestic institutional investors (DIIs) held 9.2% as of June 2026, down from 11.0% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 49.1% | 7.2% | 9.2% | 34.4% |
| Mar 2026 | 49.1% | 7.1% | 11.0% | 32.8% |
| Dec 2025 | 49.1% | 7.0% | 10.6% | 33.4% |
| Sep 2025 | 49.1% | 7.1% | 11.0% | 32.8% |
Track quarterly shareholding changes for Wockhardt Ltd. →
Wockhardt Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹81.35B, up 6.4% YoY from ₹76.49B.
Other Assets accounts for 40.7% of the total, ahead of Property, Plant & Equipment (23.2%) and Intangibles & Goodwill (12.5%).
Capital structure: 57.2% equity, 24.8% debt, 17.9% operating liabilities. Over the year, debt is down 14.2% and equity is up 27.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.34B |
| Receivables | 6.61B |
| Inventories | 7.25B |
| Property, Plant & Equipment | 18.86B |
| Intangibles & Goodwill | 10.18B |
| Other Assets | 33.11B |
| Category | Value |
|---|---|
| Equity | 46.57B |
| Short-term Debt | 7.15B |
| Long-term Debt | 13.06B |
| Trade Payables | 5.92B |
| Other Liabilities | 8.65B |
Wockhardt at a Glance
Here's the bottom line on Wockhardt Ltd. (WOCKPHARMA) based on the latest available financials.
Revenue of ₹3,012 Cr in FY2025, up 7.6% year-over-year.
Long-term revenue has been contracting at 3.9% annually over 10 years.
The company reported a net loss of ₹57.0 Cr in FY2025.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Wockhardt Ltd..